Mesenchymal and induced pluripotent stem cell-based therapeutics: a comparison

Area of Science:

• Regenerative Medicine
• Biotechnology
• Cell Therapy Manufacturing

Background:

• Human mesenchymal stem cells (hMSCs) and induced pluripotent stem cells (hiPSCs) are key players in cell therapy.
• While hMSC-based therapeutics are commercially available, hiPSC-based ones are still in development.
• Cell therapy applications span orthopedics, cardiovascular diseases, autoimmune disorders, and cancer.

Purpose of the Study:

• To compare the manufacturing processes of hMSC- and hiPSC-based cell therapies.
• To identify similarities and differences impacting production.
• To analyze characteristics, safety, ethics, morphology, cultivation, and downstream processing.

Main Methods:

• Comparative analysis of hMSC and hiPSC characteristics.
• Review of commercially available hMSC therapeutics and hiPSC candidates in clinical trials.
• Evaluation of 2D and 3D cultivation methods, culture media, and process modes.
• Discussion of downstream processing and single-use technology.

Main Results:

• hMSCs and hiPSCs exhibit distinct behaviors during cultivation.
• Single-use stirred bioreactor systems are suitable for both cell types.
• Differences in cell characteristics necessitate tailored production strategies.

Conclusions:

• Understanding cell-specific requirements is crucial for optimizing cell therapy manufacturing.
• Single-use technologies offer advantages for both hMSC and hiPSC cultivation.
• Further research should focus on adapting downstream processes for single-use systems.